Dermagnostix announces mid-term analysis of ongoing 3-year clinical utility study on PsorX classifier sponsored by the DGUV (German Accident Insurance Company) was presented at ADF.
More...
The analysis demonstrates that the Molecular Classifier supports diagnosing clinically or dermatopathologically unclear cases and reduces the number of unclear cases by >98%. After 12 months of disease progression from baseline, dermatologists’ diagnoses increase in agreement with the Molecular Classifier results by 37%. (49th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) - 2023 - Experimental Dermatology - Wiley Online Library; Poster 038)